Program
flotufolastat F 18
Also written as “rhPSMA-7.3 (18F) Injection”, “Flotufolastat F-18 Injection” and “flotufolastat (18F)”.
Its studies are mostly in Prostatic Neoplasms, led by 3 companies.
Drug pageFlotufolastat F 18: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Braccoits history only | 40 open or running | phase 4since Sep 17, 2024 | Jun 18, 2019 | none ahead |
| Sinotau Pharmaceutical Groupits history only | 20 open or running | phase 1since Aug 4, 2025 | Aug 4, 2025 | none ahead |
| Novartis | 10 open or running | phase 2since Feb 25, 2025 | Feb 25, 2025 | none ahead |
Also a collaborator on its studies: Aixial Group and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 25, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT06881823
TargetBeta
“Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells.”study text, by rule · the study
Other programs on FOLH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| piflufolastatrule | Lantheus | phase 4 | 5 |
| abefolastat tesaroxetan CU-64rule | clarity-pharmaceuticals-ltd | phase 3 | 5 |
| gallium 68 PSMA-11rule | Novartis | phase 3 | 4 |
| Lutetium Lu 177 Ludotadipeprule | futurechem | phase 3 | 3 |
| Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 | Johnson & Johnson | phase 3 | 2 |
| Lutetium Lu 177 NYM032rule | Norroy Bioscience | phase 3 | 2 |
| actinium AC-225 vipivotide tetraxetan | Novartis | phase 3 | 2 |
| HRS-4357 | Jiangsu HengRui Medicine | phase 3 | 2 |
| zadavotide guraxetan | AstraZeneca | phase 2 | 4 |
| AB-001rule | frontier-biotechnologies-inc | phase 2 | 3 |
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 2 |
| SHR-4394 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
The one study Novartis leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06881823Prostatic Neoplasms | 2 | Withdrawn | Mar 31, 2030 | 0 |
How it is read
Names in the registry
- “rhPSMA-7.3 (18F) Injection”, 3 entries
- “Flotufolastat F-18 Injection”, 2 entries
- “flotufolastat (18F)”, 1 entry
- “Flotufolastat F 18”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.